University of Connecticut, Hartford, CT Background: Platelet reactivity assays (PRAs) can predict patients' likely response to clopidogrel. We assessed the cost-effectiveness of universal compared to PRA-driven selection of ticagrelor or prasugrel for acute coronary syndrome (ACS) patients living in multiple European countries. Methods: An Markov model was used to calculate 5-year costs (2013V), qualityadjusted life-years and incremental cost-effectiveness ratios (ICERs) for 1-year of universal ticagrelor or prasugrel (given to all) compared to each agents' corresponding PRA-driven strategy (ticagrelor/prasugrel in those with high platelet reactivity [HPR, >208 on the VerifyNow P2Y12 assay, Accumetrics, San Diego, CA], others given generic clopidogrel]. We assumed patients had their index ACS event at 65-70 years of age and had a 42.7% incidence of HPR post-revascularization. The analysis was conducted from the perspective of 5 different European countries (Germany, Italy, France, Spain and The Netherlands) and used a 1-year cycle length. Efficacy and safety data for P2Y12 Inhibitors were taken from multinational randomized trials and adjusted using country-specific epidemiologic data. Results: Neither universal ticagrelor nor prasugrel were found to be cost-effective (all ICERs >40,250V/QALY) compared to their corresponding PRA-driven strategies in any of the countries evaluated (Table) . Results were sensitive to differences in P2Y12 Inhibitors costs and drug-specific relative risks of major adverse cardiac events. Monte Carlo simulation suggested universal ticagrelor or prasugrel were cost-effective in only 29-44% and 11-17% of 10,000 iterations compared to their respective PRAdriven strategies, when applying a willingness-to-pay threshold¼V30,000/QALY.
Conclusions:
The universal use of newer P2Y12 inhibitors is not likely cost-effective compared to PRA-driven strategies. 
P O S T E R S

